Salix licenses gastro drug from Alfa Wassermann
19:17 EDT 8 Aug 2012 | PharmPro
Salix Pharmaceuticals said Wednesday it has agreed to pay $10 million, plus additional payments to license an experimental extended release drug for intestinal and respiratory diseases, including Crohn's disease.The formulation of rifaximin from Alf..
Original Article: Salix licenses gastro drug from Alfa Wassermann
More From BioPortfolio on "Salix licenses gastro drug from Alfa Wassermann"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
